Skip to main
  1. Stocks
  2. Inhibikase Therapeutics
  3. Forecast
IKT

Inhibikase Therapeutics (IKT) Stock Forecast & Price Target

Inhibikase Therapeutics (IKT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Inhibikase Therapeutics is attractive because IKT-001 targets a clinically validated PAH biology with an oral prodrug designed to preserve imatinib’s anti-remodeling efficacy while improving the GI tolerability that constrained prior adoption. The adaptive Phase 3 IMPROVE-PAH program is already underway, with approvals in 28 countries, 79 of 180 sites activated, and a planned interim safety readout for Part A in 1H27, creating multiple near-term catalysts while potentially accelerating development by about 3 years. Financially, the company ended 3Q26 with $193.3M in cash, cash equivalents and marketable securities, reported a $0.10 per-share net loss, and appears funded through the conclusion of IMPROVE-PAH if warrant exercise proceeds as expected.

Bears say

Inhibikase Therapeutics is a high-risk clinical-stage company whose value depends overwhelmingly on IKT-001 succeeding in PAH, yet the program still must prove that a differentiated pharmacokinetic profile can improve tolerability without sacrificing efficacy. Historical imatinib data show meaningful safety concerns, including edema, bleeding, hepatic and hematologic events, with eight subdural hematomas reported across IMPRES and its extension, while IMPROVE-PAH excludes several high-risk populations and concomitant sotatercept, potentially narrowing the market and limiting combination positioning. The company also has a thin cash position, having raised $4M in May 2024 against $13.3M at YE2023, and faces dilution risk, delayed readouts, manufacturing and regulatory hurdles, and a more competitive PAH landscape that raises the bar for success.

Inhibikase Therapeutics (IKT) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inhibikase Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Inhibikase Therapeutics (IKT) Analyst Forecast & Price Prediction

Get the latest Inhibikase Therapeutics (IKT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Inhibikase Therapeutics (IKT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inhibikase Therapeutics (IKT) Forecast

Analysts have given Inhibikase Therapeutics (IKT) a Buy based on their latest research and market trends.

According to 7 analysts, Inhibikase Therapeutics (IKT) has a Buy consensus rating as of Nov 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inhibikase Therapeutics (IKT)


Inhibikase Therapeutics (IKT) Analyst Forecast & Price Prediction

Get the latest Inhibikase Therapeutics (IKT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Inhibikase Therapeutics (IKT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IKT stock data and trends